Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Radient Selling its China Subsidiary, Jade Pharma

publication date: Apr 14, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Radient Pharmaceuticals currently expects prospective purchasers of its China subsidiary, Jade Pharmaceutical, Inc. to complete their due diligence by the end of May 2010. Radient, which announced plans to divest itself of Jade in Q3 of 2009, places a $20 million value on Jade. It owns 98% of the China enterprise, though Radient doesn’t expect to realize nearly that much upon the sale. More details...

Stock Symbol: (NYSE Amex: RPC)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...